Clinical Trial Update: Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brentuximab vedotin in relapsed or refractory EBV-positive, CD30-positive lymphomas; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Relapsed or Refractory EBV-and CD30-positive Lymphomas | Phase 2 | Status: COMPLETED | Results posted: 2024-09-23